Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

NCT03637543 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Nivolumab

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

[object Object]
[object Object]